Jardiance (Empagliflozin) Does Lower NT-proBNP Levels
Yes, empagliflozin significantly reduces NT-proBNP levels in patients with heart failure, with or without type 2 diabetes. This biomarker reduction occurs alongside meaningful improvements in clinical outcomes including reduced hospitalizations and cardiovascular mortality.
Evidence from Major Clinical Trials
EMPEROR-Reduced Trial Findings
In the EMPEROR-Reduced trial, empagliflozin demonstrated consistent NT-proBNP reduction across all measured timepoints 1. By 52 weeks, empagliflozin produced a 13% adjusted mean reduction in NT-proBNP compared to placebo (P < 0.001) 1. This biomarker improvement translated directly into clinical benefit—patients achieving NT-proBNP levels in the lowest quartile (<1,115 pg/mL) by 12 weeks after starting treatment had substantially lower risk for subsequent cardiovascular death or heart failure hospitalization, regardless of their baseline concentration 1. Importantly, empagliflozin increased the odds of achieving this favorable NT-proBNP threshold by 27% compared to placebo (P = 0.01) 1.
The trial enrolled patients with heart failure and reduced ejection fraction (LVEF ≤40%) who had elevated NT-proBNP levels at baseline 2. During median 16-month follow-up, the primary outcome of cardiovascular death or heart failure hospitalization occurred in 19.4% of empagliflozin-treated patients versus 24.7% on placebo (HR 0.75,95% CI 0.65-0.86, P < 0.001) 2.
EMPEROR-Preserved Trial Results
For patients with preserved ejection fraction (LVEF >40%), the EMPEROR-Preserved trial showed empagliflozin modestly but significantly reduced NT-proBNP levels, with a 7% adjusted mean difference from placebo by 100 weeks 3. While the magnitude was smaller than in reduced ejection fraction, the benefit on clinical outcomes remained robust—a 21% reduction in the composite of cardiovascular death or heart failure hospitalization (HR 0.79,95% CI 0.69-0.90, P < 0.001) 4.
Real-World Clinical Evidence
Acute Decompensated Heart Failure
In hospitalized patients with type 2 diabetes and acute decompensated heart failure, continuing empagliflozin as add-on therapy produced significantly lower NT-proBNP levels at discharge compared to conventional insulin therapy (1,699±522 vs 2,303±598 pg/mL, P = 0.021) 5. This occurred alongside improved decongestion markers without increased risk of worsening renal function 5.
A separate study in very old patients (≥80 years) hospitalized for acute heart failure confirmed these findings, showing lower NT-proBNP at discharge with empagliflozin continuation versus basal-bolus insulin 6.
Chronic Stable Heart Failure
In a recent prospective study of patients with stable chronic heart failure, both empagliflozin and dapagliflozin maintained NT-proBNP levels without significant changes after crossover between agents, suggesting comparable effects 7. A real-world observational study demonstrated statistically significant reductions in both NT-proBNP and HbA1c levels at 90 days in patients with type 2 diabetes and heart failure treated with empagliflozin, while preserving renal function 8.
Clinical Implications and Mechanism
The NT-proBNP reduction with empagliflozin reflects genuine improvement in cardiac hemodynamics and volume status, not merely biomarker manipulation. The drug achieves effective decongestion through its diuretic and natriuretic effects 5. Patients with heart failure with reduced ejection fraction showed more pronounced NT-proBNP reductions—those with HFrEF were 11.42 times more likely to achieve NT-proBNP reductions >300 pg/mL compared to HFpEF patients (OR 11.42, P = 0.028) 8.
Guideline-Recommended Use
Current guidelines strongly recommend SGLT2 inhibitors including empagliflozin as foundational therapy for heart failure across the ejection fraction spectrum 9, 2. The 2025 Canadian Cardiovascular Society/Canadian Heart Failure Society guidelines list empagliflozin 10 mg daily as standard dosing for heart failure with nonreduced ejection fraction, with option to increase to 25 mg daily 9. The 2022 AHA/ACC/HFSA guidelines provide a Strong Recommendation with High-Quality Evidence for SGLT2 inhibitor use in HFrEF to improve symptoms, quality of life, and reduce heart failure hospitalization and cardiovascular mortality 10.
Important Caveats
- NT-proBNP concentration after treatment initiation better informs prognosis than pretreatment levels 1
- Higher baseline NT-proBNP predicts greater absolute risk, but empagliflozin's relative benefit is consistent across all baseline concentrations 1, 3
- The biomarker reduction occurs early (detectable by 4 weeks) and is sustained long-term 1
- Benefits occur independent of diabetes status and baseline glycemic control 2